Literature DB >> 32770557

Taking the brake off the immune system: Hypotheses, trials, tribulations, and the evolving discipline of clinical immunopharmacology.

Jennifer H Martin1, Lionel D Lewis2.   

Abstract

Mesh：

Year:  2020        PMID： 32770557      PMCID： PMC7444765          DOI： 10.1111/bcp.14481

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  15 in total

1.  Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Authors:  Nicholas S Downing; Jenerius A Aminawung; Nilay D Shah; Harlan M Krumholz; Joseph S Ross
Journal:  JAMA       Date:  2014 Jan 22-29       Impact factor: 56.272

Review 2.  Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies.

Authors:  Yara Abdou; Manu Pandey; Maithreyi Sarma; Shrunjal Shah; Jeffrey Baron; Marc S Ernstoff
Journal:  Br J Clin Pharmacol       Date:  2020-05-12       Impact factor: 4.335

Review 3.  Cost-effectiveness and financial risks associated with immune checkpoint inhibitor therapy.

Authors:  Hansoo Kim; Danny Liew; Stephen Goodall
Journal:  Br J Clin Pharmacol       Date:  2020-06-18       Impact factor: 4.335

Review 4.  Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.

Authors:  Vishal Navani; Moira C Graves; Nikola A Bowden; Andre Van Der Westhuizen
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

5.  Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.

Authors:  Jeremy M O'Connor; Kristen L Fessele; Jean Steiner; Kathi Seidl-Rathkopf; Kenneth R Carson; Nathan C Nussbaum; Emily S Yin; Kerin B Adelson; Carolyn J Presley; Anne C Chiang; Joseph S Ross; Amy P Abernethy; Cary P Gross
Journal:  JAMA Oncol       Date:  2018-08-09       Impact factor: 31.777

Review 6.  Chimeric antigen receptor T-cell therapies: Optimising the dose.

Authors:  Nathaniel Dasyam; Philip George; Robert Weinkove
Journal:  Br J Clin Pharmacol       Date:  2020-03-24       Impact factor: 4.335

Review 7.  Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?

Authors:  Geoffrey Alan Watson; Jeffrey Doi; Aaron Richard Hansen; Anna Spreafico
Journal:  Br J Clin Pharmacol       Date:  2020-06-13       Impact factor: 4.335

Review 8.  Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.

Authors:  Hui Yi Chew; Riccardo Dolcetti; Fiona Simpson
Journal:  Br J Clin Pharmacol       Date:  2020-06-18       Impact factor: 4.335

Review 9.  Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.

Authors:  Cody J Peer; Daniel A Goldstein; Jennifer C Goodell; Ryan Nguyen; William D Figg; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2020-06-11       Impact factor: 3.716

Review 10.  The influence of diet on anti-cancer immune responsiveness.

Authors:  Laura Soldati; Laura Di Renzo; Emilio Jirillo; Paolo A Ascierto; Francesco M Marincola; Antonino De Lorenzo
Journal:  J Transl Med       Date:  2018-03-20       Impact factor: 5.531
View more
  1 in total

1.  Melanoma: An immunotherapy journey from bench to bedside.

Authors:  Vishal Navani; Moira C Graves; Hiren Mandaliya; Martin Hong; Andre van der Westhuizen; Jennifer Martin; Nikola A Bowden
Journal:  Cancer Treat Res       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.